**About PIONEER**

**Prostate Cancer DiagnOsis and TreatmeNT Enhancement through the Power of Big Data in EuRope (PIONEER)**

- An IMI2 funded public-private pan-European Network of Excellence for Big Data in Prostate Cancer.
- One of the EU’s Big Data for Better Outcomes disease projects.
- Consist of 32 stakeholders from across 9 countries.
- PIONEER is using a vast amount of available “big data” to improve screening, diagnosis and treatment of prostate cancer.

**PIONEER’s vision**

PIONEERs vision is to re-orient the management and clinical practice of prostate cancer towards a more outcome-driven, value-based and patient-centric healthcare system for all European men living with prostate cancer.

**8 work packages with specific tasks**

1. WP1: Project management & administration
2. WP2: Outcome definitions
3. WP3: Data access & sources
4. WP4: Data Platform
5. WP5: Data analytics
6. WP6: HTA/Regulator/payer integration

**Target contributors**

- Academic & Research Institutions
- Clinicians & Pharmaceutical Companies
- Information & Technology Specialists
- Patients and Patient Organisations
- Regulatory agencies & HTA bodies

**Identified data sources**

Over 80 European and non-European prostate cancer-based databases have been identified.

**EU-based data sources identified from:**

- EU
- Sweden
- Netherlands
- Finland
- Ireland
- Germany
- Denmark
- Italy
- Belgium
- Spain

**Non-EU data sources identified from:**

- USA
- Israel
- Norway
- Australia
- New Zealand
- Canada
- Brazil
- UK

**How to contribute**

PIONEER coordinator: James N'Dow, MD, PhD
jndow@abdn.ac.uk

PIONEER Deputy coordinator: Anders Bjartell, MD, PhD
Anders.Bjartell@med.lu.se

WP3 coordinator: Susan Evans-Axelsson, PhD
Susan.Evans-Axelsson@med.lu.se

PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492 and is part of the Big Data for Better Outcomes Programme (BD4BO). IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).